Cognition Therapeutics Inc (CGTX) · Oct 22, 2026 · Other events
FDA alignment — 100 mg daily vs placebo for nine months; NPI-2 primary endpoint
Cognition Therapeutics gets FDA alignment on zervimesine’s DLB Phase 3 design, reducing protocol risk—but the trial is still being finalized.
Cognition Therapeutics is a clinical-stage biotech narrowing its lead program around zervimesine for dementia with Lewy bodies, after earlier FDA discussions had already clarified the planned pivotal path and the company targeted a Phase 3 start in mid-2027.
The regulatory path is now more defined, but not fundamentally new. The company says FDA aligned on patient selection, dose, trial duration, and endpoints. 〔0〕 That reduces protocol uncertainty, but the meeting and general alignment were already anticipated after the September announcement of a Type C meeting and prior FDA feedback.
The filing adds useful design specifics rather than clinical proof. The planned study would test 100 mg of once-daily zervimesine against placebo for nine months in mild-to-moderate DLB, with hallucinations and delusions measured by NPI-2 as the primary endpoint and daily function as a key secondary endpoint. 〔1〕 〔2〕
This advances execution, not the drug’s efficacy case. There is no new patient enrollment, trial start, efficacy result, approval, or financing in the filing; management says it is still completing the protocol. 〔3〕 The business remains dependent on reproducing the earlier Phase 2 signal in a registrational study, so the event is best read as a partly expected regulatory de-risking rather than a major change in the underlying clinical odds.
Bottom line: FDA agreement makes the DLB Phase 3 plan more concrete, but this is confirmation and preparation—not a trial launch or efficacy milestone. It matters operationally, while leaving the central clinical risk unchanged.
Phase 3 initiation, targeted mid-2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!